Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients

References

1. ↵
   1. Rambaldi GZ,
   2. Giannotta M,
   3. Vocale C,
   4. Landini MP,
   5. Zompatori M

   (2017) Chest x-ray and HRCT findings in influenza A/B pneumonia as a predictor of clinical course and intensive care hospitalisation (European Congress of Radiology, Austria).
2. ↵
   1. Grohskopf LA,
   2. Alyanak E,
   3. Broder KR,
   4. Walter EB,
   5. Fry AM,
   6. Jernigan DB

   (2019) Prevention and control of seasonal influenza with vaccines:recommendations of the Advisory Committee on Immunization Practices-United States 2019-20 influenza season. MMWR Recommendations and Reports 68:1.
3. ↵
   1. Dai Z,
   2. Zhang L,
   3. Yu Q,
   4. Liu L,
   5. Yang M,
   6. Fan K

   (2020) Early administration of oseltamivir within 48 hours after onset of flulike symptoms can reduce the risk of influenza B Virus-Associated Pneumonia in hospitalized pediatric patients with influenza B virus infection. Pediatr Infect Dis J 39:e20–e22.
4. ↵
   1. Fry AM,
   2. Goswami D,
   3. Nahar K,
   4. Sharmin AT,
   5. Rahman M,
   6. Gubareva L,
   7. et al.

   (2014) Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh:a randomised placebo-controlled trial. Lancet Infect Dis 14:109–118.
5. ↵
   1. Beigel JH,
   2. Bao Y,
   3. Beeler J,
   4. Manosuthi W,
   5. Slandzicki A,
   6. Dar SM,
   7. et al.

   (2017) Oseltamivir, amantadine, and ribavirin combination antiviral therapy versus oseltamivir monotherapy for the treatment of influenza:a multicentre, double-blind, randomised phase 2 trial. Lancet Infect Dis 17:1255–1265.
6. ↵
   1. Hung IF,
   2. To KK,
   3. Chan JF,
   4. Cheng VC,
   5. Liu KS,
   6. Tam A,
   7. et al.

   (2017) Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A (H3N2) infection:an open-label randomized, controlled, phase IIb/III trial. Chest 151:1069–1080.
7. ↵
   1. Kakeya H,
   2. Seki M,
   3. Izumikawa K,
   4. Kosai K,
   5. Morinaga Y,
   6. Kurihara S,
   7. et al.

   (2014) Efficacy of combination therapy with oseltamivir phosphate and azithromycin for influenza:a multicenter, open-label, randomized study. PLoS One 9:e91293.
8. ↵
   1. Ishaqui AA,
   2. Khan AH,
   3. Sulaiman SAS,
   4. Alsultan MT,
   5. Khan I,
   6. Naqvi AA

   (2020) Assessment of efficacy of oseltamivir-azithromycin combination therapy in prevention of influenza-a (H1N1) infection complications and rapidity of symptom relief. Expert Rev Respir Med 14:533–541.
9. ↵
   1. Chen S,
   2. Liu G,
   3. Hu A,
   4. Zhang L,
   5. Sun W,
   6. Tang W,
   7. et al.

   (2019) Ponatinib Protects Mice from Lethal Influenza Infection by Suppressing Cytokine Storm. Front Immunol 10:393.
10. ↵
    1. Kwiatkowska B,
    2. Maślińska M

    (2012) Macrolide therapy in chronic inflammatory diseases. Mediators Inflamm 2012:636157.
11. ↵
    1. Lee N,
    2. Wong C-K,
    3. Chan MC,
    4. Yeung ES,
    5. Tam WW,
    6. Tsang OT,
    7. et al.

    (2017) Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza:a randomized controlled trial. Antiviral Res 144:48–56.
12. ↵
    1. Falsey AR,
    2. Baran A,
    3. Walsh EE

    (2015) Should clinical case definitions of influenza in hospitalized older adults include fever? Influenza Other Respir Viruses 9(Suppl1):23–29.
13. ↵
    1. Carrat F,
    2. Vergu E,
    3. Ferguson NM,
    4. Lemaitre M,
    5. Cauchemez S,
    6. Leach S,
    7. et al.

    (2008) Time lines of infection and disease in human influenza:a review of volunteer challenge studies. Am J Epidemiol 167:775–785.
14. ↵
    1. Shaik AB,
    2. Prabhu M,
    3. Shenoy S,
    4. Thomson SR

    (2018) Oseltamivir-induced neuropsychiatric symptoms. Journal of Pharmacology and Pharmacotherapeutics 9:43.
15. ↵
    1. Schmidt S

    (2015) Complications of flu. SA Pharmaceutical Journal 82:23–27.